Legend Biotech Secures New Headquarters in Bridgewater

Legend Biotech ( (LEGN) ) just unveiled an update.

On May 9, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, entered into a lease agreement for a new global corporate headquarters in Bridgewater, New Jersey. The lease, which begins on June 1, 2025, and runs until April 2036, includes options for extension and rights to additional office space. This move is expected to enhance Legend Biotech’s operational capabilities and strengthen its industry positioning.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s stock is rated at 45, reflecting significant growth potential tempered by challenges in profitability and technical performance. The financial performance indicates strong revenue growth but highlights concerns around profitability and cash flow. Technical analysis suggests bearish trends, and valuation challenges are evident with a negative P/E ratio. However, the recent earnings call provides optimism with robust sales growth and strategic expansions, suggesting potential improvement in the company’s financial health.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel therapies. The company is known for its innovative approach to cancer treatment and has a significant market focus on cell therapies.

Average Trading Volume: 1,388,216

Technical Sentiment Signal: Sell

Current Market Cap: $5.95B

See more data about LEGN stock on TipRanks’ Stock Analysis page.